Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetics and Genomics Program, |
RCV001293205 | SCV001434203 | uncertain significance | Hypertrophic cardiomyopathy | criteria provided, single submitter | research | ||
Ambry Genetics | RCV002354910 | SCV002620115 | uncertain significance | Cardiovascular phenotype | 2019-05-29 | criteria provided, single submitter | clinical testing | The p.R12650Q variant (also known as c.37949G>A), located in coding exon 138 of the TTN gene, results from a G to A substitution at nucleotide position 37949. The arginine at codon 12650 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003141918 | SCV003821704 | uncertain significance | not provided | 2021-10-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004544998 | SCV004770331 | uncertain significance | TTN-related disorder | 2024-01-26 | no assertion criteria provided | clinical testing | The TTN c.65144G>A variant is predicted to result in the amino acid substitution p.Arg21715Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.020% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |